What is the appropriate enoxaparin dosing for a 70‑kg adult with STEMI or NSTEMI, including adjustments for renal impairment and contraindications?

Enoxaparin Dosing in STEMI/NSTEMI

For a 70-kg adult with STEMI or NSTEMI and normal renal function, administer enoxaparin 1 mg/kg (70 mg) subcutaneously every 12 hours, with specific age-based and renal adjustments as outlined below.

STEMI with Fibrinolytic Therapy

For STEMI patients receiving fibrinolytic therapy, the dosing strategy differs by age 1:

Age <75 years:

• 30 mg IV bolus initially
• Followed in 15 minutes by 1 mg/kg SC every 12 hours (maximum 100 mg for first 2 doses)
• For your 70-kg patient: 30 mg IV bolus, then 70 mg SC every 12 hours
• Duration: Up to 8 days or until revascularization

Age ≥75 years:

• NO IV bolus
• 0.75 mg/kg SC every 12 hours (maximum 75 mg for first 2 doses)
• For a 70-kg patient: 52.5 mg SC every 12 hours

NSTEMI (Non-ST-Elevation ACS)

For NSTEMI patients, regardless of invasive versus conservative strategy 2:

Standard dosing:

• 1 mg/kg SC every 12 hours (70 mg for your 70-kg patient)
• An initial 30 mg IV loading dose has been used in selected patients
• Continue for duration of hospitalization or until PCI

If undergoing PCI:

• If <2 therapeutic SC doses given OR last SC dose was 8-12 hours before PCI: administer additional 0.3 mg/kg IV (21 mg for 70-kg patient) at time of PCI 2
• If ≥2 doses given and last dose within 8 hours: no additional dosing needed

Critical Renal Adjustments

CrCl <30 mL/min (regardless of age or indication):

• 1 mg/kg SC once daily (every 24 hours, not every 12 hours) 1, 2
• This is a crucial adjustment—failure to reduce frequency significantly increases bleeding risk 3, 4

CrCl 30-50 mL/min:

• Guidelines recommend standard dosing, but pharmacokinetic data show 31% decreased clearance in moderate renal impairment 3
• Consider dose reduction to 0.8 mg/kg every 12 hours in this range to avoid accumulation 3

Absolute Contraindications

• Active major bleeding
• Severe thrombocytopenia (platelet count <50,000/mm³)
• History of heparin-induced thrombocytopenia (HIT)
• Hypersensitivity to enoxaparin, heparin, or pork products
• CrCl <30 mL/min is NOT a contraindication but requires dose adjustment to once daily

Common Pitfalls to Avoid

1. Forgetting the age adjustment in STEMI with fibrinolysis: Patients ≥75 years had doubled intracranial bleeding rates with the IV bolus in early studies 5—omit the bolus in elderly patients

2. Missing renal impairment: Always calculate CrCl before initiating therapy. The two-tiered FDA dosing scheme (normal vs. CrCl <30) may be insufficient—moderate impairment (CrCl 30-50) shows significant drug accumulation 4

3. Inadequate dosing at PCI: If patient received upstream enoxaparin but last dose was >8 hours ago or <2 doses total, give 0.3 mg/kg IV bolus to prevent catheter thrombosis 2

4. Continuing beyond indicated duration: Discontinue after PCI unless compelling reason exists (e.g., atrial fibrillation, LV thrombus) 2

5. Maximum dose caps: First 2 doses capped at 100 mg for age <75 years, 75 mg for age ≥75 years in STEMI with fibrinolysis 1

Monitoring Considerations

While routine anti-Xa monitoring is not required, consider checking levels in:

• Extremes of body weight (BMI >40 or <18.5 kg/m²)
• Renal impairment (especially CrCl 30-50 mL/min)
• Unexplained bleeding or recurrent thrombosis
• Target prophylactic range: 0.5-1.2 IU/mL (peak, 4 hours post-dose)

The evidence strongly supports enoxaparin over unfractionated heparin in both STEMI and NSTEMI for reducing reinfarction and mortality, with comparable or lower bleeding rates when dosed appropriately 1, 2, 5.